Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 483

1.

Key issues that need to be considered while revising the current Annex of the European Council Recommendation (2003) on cancer screening.

Ponti A, Basu P, Ritchie D, Anttila A, Carvalho AL, Senore C, Mallafré-Larrosa M, Piccinelli C, Ronco G, Soerjomataram I, Primic-Žakelj M, Dillner J, Elfström MK, Lönnberg S, Vale DB, Tomatis M, Armaroli P, Giordano L, Sankaranarayanan R, Segnan N.

Int J Cancer. 2020 Jan 22. doi: 10.1002/ijc.32885. [Epub ahead of print] Review.

PMID:
31970768
2.

Human papillomavirus types in cervical dysplasia among young HPV-vaccinated women: Population-based nested case-control study.

Kann H, Hortlund M, Eklund C, Dillner J, Faust H.

Int J Cancer. 2019 Dec 23. doi: 10.1002/ijc.32848. [Epub ahead of print]

PMID:
31868230
3.

Sequencing detects human papillomavirus in some apparently HPV-negative invasive cervical cancers.

Arroyo Mühr LS, Lagheden C, Eklund C, Lei J, Nordqvist-Kleppe S, Sparén P, Sundström K, Dillner J.

J Gen Virol. 2019 Dec 20. doi: 10.1099/jgv.0.001374. [Epub ahead of print]

PMID:
31859615
4.

Baseline findings and safety of infrequent vs. frequent screening of human papillomavirus vaccinated women.

Louvanto K, Eriksson T, Gray P, Apter D, Baussano I, Bly A, Harjula K, Heikkilä K, Hokkanen M, Huhtinen L, Ikonen M, Karttunen H, Nummela M, Söderlund-Strand A, Veivo U, Dillner J, Elfstöm M, Nieminen P, Lehtinen M.

Int J Cancer. 2019 Nov 20. doi: 10.1002/ijc.32802. [Epub ahead of print]

PMID:
31749143
5.

Colposcopic and histopathologic evaluation of women with HPV persistence exiting an organized screening program.

Sahlgren H, Elfström KM, Lamin H, Carlsten-Thor A, Eklund C, Dillner J, Elfgren K.

Am J Obstet Gynecol. 2019 Oct 1. pii: S0002-9378(19)31204-9. doi: 10.1016/j.ajog.2019.09.039. [Epub ahead of print]

PMID:
31585095
6.

ViraMiner: Deep learning on raw DNA sequences for identifying viral genomes in human samples.

Tampuu A, Bzhalava Z, Dillner J, Vicente R.

PLoS One. 2019 Sep 11;14(9):e0222271. doi: 10.1371/journal.pone.0222271. eCollection 2019.

7.

Author's reply to: Human papillomavirus type 197 is not associated with skin tumors.

Arroyo Mühr LS, Dillner J.

Int J Cancer. 2019 Dec 1;145(11):3181. doi: 10.1002/ijc.32645. Epub 2019 Sep 10. No abstract available.

PMID:
31456228
8.

Response to the author: invitation to cancer screening: putting the car before the horse?

Vale DB, Anttila A, Ponti A, Senore C, Sankaranaryanan R, Ronco G, Segnan N, Tomatis M, Žakelj MP, Elfström KM, Lönnberg S, Dillner J, Basu P.

Eur J Cancer Prev. 2019 Sep;28(5):458-459. doi: 10.1097/CEJ.0000000000000474. No abstract available.

PMID:
31385844
9.

Methylation in predicting progression of untreated high-grade cervical intraepithelial neoplasia.

Louvanto K, Aro K, Nedjai B, Bützow R, Jakobsson M, Kalliala I, Dillner J, Nieminen P, Lorincz A.

Clin Infect Dis. 2019 Jul 25. pii: ciz677. doi: 10.1093/cid/ciz677. [Epub ahead of print]

PMID:
31344234
10.

The HPV16 Genome Is Stable in Women Who Progress to In Situ or Invasive Cervical Cancer: A Prospective Population-Based Study.

Arroyo-Mühr LS, Lagheden C, Hultin E, Eklund C, Adami HO, Dillner J, Sundström K.

Cancer Res. 2019 Sep 1;79(17):4532-4538. doi: 10.1158/0008-5472.CAN-18-3933. Epub 2019 Jul 9.

PMID:
31289133
11.

Age-specific HPV type distribution in high-grade cervical disease in screened and unvaccinated women.

Aro K, Nieminen P, Louvanto K, Jakobsson M, Virtanen S, Lehtinen M, Dillner J, Kalliala I.

Gynecol Oncol. 2019 Aug;154(2):354-359. doi: 10.1016/j.ygyno.2019.05.024. Epub 2019 Jun 5.

12.

HPV transcription in skin tumors.

Hultin E, Arroyo Mühr LS, Lagheden C, Dillner J.

PLoS One. 2019 May 31;14(5):e0217942. doi: 10.1371/journal.pone.0217942. eCollection 2019.

13.

Cervical cancer case-control audit: Results from routine evaluation of a nationwide cervical screening program.

Wang J, Elfström KM, Andrae B, Nordqvist Kleppe S, Ploner A, Lei J, Dillner J, Sundström K, Sparén P.

Int J Cancer. 2020 Mar 1;146(5):1230-1240. doi: 10.1002/ijc.32416. Epub 2019 Jun 3.

14.

NordScreen - an interactive tool for presenting cervical cancer screening indicators in the Nordic countries.

Partanen VM, Anttila A, Heinävaara S, Pankakoski M, Sarkeala T, Bzhalava Z, Elfström KM, Tropé A, Skare GB, Thorsteinsdottir S, Ágústsson ÁI, Veerus P, Koreinik L, Dillner J, Lönnberg S.

Acta Oncol. 2019 Sep;58(9):1199-1204. doi: 10.1080/0284186X.2019.1615637. Epub 2019 May 20.

PMID:
31106635
15.

WITHDRAWAL-Administrative Duplicate Publication: The essential role of prevention in reducing the cancer burden in Europe: a commentary from Cancer Prevention Europe.

Espina C, Bauld L, Bonanni B, Brenner H, Brown K, Dillner J, Kampman E, Nilbert M, Vineis P, Weijenberg MP, Cox A, de Kok TM, Fecht D, Mitrou G, Muller DC, Serrano D, Steindorf K, Storm H, Thorat MA, van Duijnhoven F, Weiderpass E, Schüz J.

Tumori. 2019 May 17:300891619851865. doi: 10.1177/0300891619851865. [Epub ahead of print] No abstract available. Erratum in: Tumori. 2019 Aug 27;:300891619867815.

16.

Increasing participation in cervical screening by targeting long-term nonattenders: Randomized health services study.

Elfström KM, Sundström K, Andersson S, Bzhalava Z, Carlsten Thor A, Gzoul Z, Öhman D, Lamin H, Eklund C, Dillner J, Törnberg S.

Int J Cancer. 2019 Dec 1;145(11):3033-3039. doi: 10.1002/ijc.32374. Epub 2019 May 10.

PMID:
31032904
17.

Roadmap for a precision-medicine initiative in the Nordic region.

Njølstad PR, Andreassen OA, Brunak S, Børglum AD, Dillner J, Esko T, Franks PW, Freimer N, Groop L, Heimer H, Hougaard DM, Hovig E, Hveem K, Jalanko A, Kaprio J, Knudsen GP, Melbye M, Metspalu A, Mortensen PB, Palmgren J, Palotie A, Reed W, Stefánsson H, Stitziel NO, Sullivan PF, Thorsteinsdóttir U, Vaudel M, Vuorio E, Werge T, Stoltenberg C, Stefánsson K.

Nat Genet. 2019 Jun;51(6):924-930. doi: 10.1038/s41588-019-0391-1. No abstract available.

PMID:
30988515
18.

Cervical screening and risk of adenosquamous and rare histological types of invasive cervical carcinoma: population based nested case-control study.

Lei J, Andrae B, Ploner A, Lagheden C, Eklund C, Nordqvist Kleppe S, Wang J, Fang F, Dillner J, Elfström KM, Sparén P.

BMJ. 2019 Apr 3;365:l1207. doi: 10.1136/bmj.l1207.

19.

A novel human in vitro papillomavirus type 16 positive tonsil cancer cell line with high sensitivity to radiation and cisplatin.

Forslund O, Sugiyama N, Wu C, Ravi N, Jin Y, Swoboda S, Andersson F, Bzhalava D, Hultin E, Paulsson K, Dillner J, Schwartz S, Wennerberg J, Ekblad L.

BMC Cancer. 2019 Mar 25;19(1):265. doi: 10.1186/s12885-019-5469-8.

20.

Some clear answers regarding transmission of genital human papillomavirus.

Dillner J.

Lancet Infect Dis. 2019 Mar;19(3):227-228. doi: 10.1016/S1473-3099(19)30048-9. Epub 2019 Feb 10. No abstract available.

PMID:
30745275
21.

Occurrence of human papillomavirus (HPV) type replacement by sexual risk-taking behaviour group: Post-hoc analysis of a community randomized clinical trial up to 9 years after vaccination (IV).

Gray P, Luostarinen T, Vänskä S, Eriksson T, Lagheden C, Man I, Palmroth J, Pimenoff VN, Söderlund-Strand A, Dillner J, Lehtinen M.

Int J Cancer. 2019 Aug 1;145(3):785-796. doi: 10.1002/ijc.32189. Epub 2019 Feb 28.

PMID:
30719706
22.

Human papillomavirus genotype distribution and socio-behavioural characteristics in women with cervical pre-cancer and cancer at the start of a human papillomavirus vaccination programme: the CIN3+ plus study.

Egli-Gany D, Spaar Zographos A, Diebold J, Masserey Spicher V, Frey Tirri B, Heusser R, Dillner J, Petignat P, Sahli R, Low N; CIN3+plus study group.

BMC Cancer. 2019 Jan 30;19(1):111. doi: 10.1186/s12885-018-5248-y.

23.

Early detection and prevention.

Dillner J.

Mol Oncol. 2019 Mar;13(3):591-598. doi: 10.1002/1878-0261.12459. Epub 2019 Feb 27. Review.

24.

Cancer Prevention Europe.

Wild CP, Espina C, Bauld L, Bonanni B, Brenner H, Brown K, Dillner J, Forman D, Kampman E, Nilbert M, Steindorf K, Storm H, Vineis P, Baumann M, Schüz J.

Mol Oncol. 2019 Mar;13(3):528-534. doi: 10.1002/1878-0261.12455. Epub 2019 Feb 13. Review.

25.

Eradication of human papillomavirus and elimination of HPV-related diseases - scientific basis for global public health policies.

Lehtinen M, Baussano I, Paavonen J, Vänskä S, Dillner J.

Expert Rev Vaccines. 2019 Feb;18(2):153-160. doi: 10.1080/14760584.2019.1568876. Epub 2019 Feb 7. Review.

PMID:
30657348
26.

The Launch of an International Animal Papillomavirus Reference Center.

Van Doorslaer K, Dillner J.

Viruses. 2019 Jan 14;11(1). pii: E55. doi: 10.3390/v11010055.

27.

Human papillomavirus types in cervical high-grade lesions or cancer among Nordic women-Potential for prevention.

Dovey de la Cour C, Guleria S, Nygård M, Trygvadóttir L, Sigurdsson K, Liaw KL, Hortlund M, Lagheden C, Hansen BT, Munk C, Dillner J, Kjaer SK.

Cancer Med. 2019 Feb;8(2):839-849. doi: 10.1002/cam4.1961. Epub 2019 Jan 11.

28.

Cervical cancer screening in Sweden 2014-2016.

Hortlund M, Elfström KM, Sparén P, Almstedt P, Strander B, Dillner J.

PLoS One. 2018 Dec 17;13(12):e0209003. doi: 10.1371/journal.pone.0209003. eCollection 2018.

29.

Performance of colorectal cancer screening in the European Union Member States: data from the second European screening report.

Senore C, Basu P, Anttila A, Ponti A, Tomatis M, Vale DB, Ronco G, Soerjomataram I, Primic-Žakelj M, Riggi E, Dillner J, Elfström MK, Lönnberg S, Sankaranarayanan R, Segnan N.

Gut. 2019 Jul;68(7):1232-1244. doi: 10.1136/gutjnl-2018-317293. Epub 2018 Dec 10.

PMID:
30530530
30.

Human papillomavirus type 16 genomic variation in women with subsequent in situ or invasive cervical cancer: prospective population-based study.

Arroyo-Mühr LS, Lagheden C, Hultin E, Eklund C, Adami HO, Dillner J, Sundström K.

Br J Cancer. 2018 Oct;119(9):1163-1168. doi: 10.1038/s41416-018-0311-7. Epub 2018 Oct 22.

31.

High-risk human papillomavirus status and prognosis in invasive cervical cancer: A nationwide cohort study.

Lei J, Ploner A, Lagheden C, Eklund C, Nordqvist Kleppe S, Andrae B, Elfström KM, Dillner J, Sparén P, Sundström K.

PLoS Med. 2018 Oct 1;15(10):e1002666. doi: 10.1371/journal.pmed.1002666. eCollection 2018 Oct.

32.

The Valgent4 protocol: Robust analytical and clinical validation of 11 HPV assays with genotyping on cervical samples collected in SurePath medium.

Bonde J, Ejegod DM, Cuschieri K, Dillner J, Heideman DAM, Quint W, Pavon Ribas MA, Padalko E, Christiansen IK, Xu L, Arbyn M.

J Clin Virol. 2018 Nov;108:64-71. doi: 10.1016/j.jcv.2018.09.012. Epub 2018 Sep 17.

33.

Machine Learning for detection of viral sequences in human metagenomic datasets.

Bzhalava Z, Tampuu A, Bała P, Vicente R, Dillner J.

BMC Bioinformatics. 2018 Sep 24;19(1):336. doi: 10.1186/s12859-018-2340-x.

34.

Long-term Antibody Response to Human Papillomavirus Vaccines: Up to 12 Years of Follow-up in the Finnish Maternity Cohort.

Artemchuk H, Eriksson T, Poljak M, Surcel HM, Dillner J, Lehtinen M, Faust H.

J Infect Dis. 2019 Jan 29;219(4):582-589. doi: 10.1093/infdis/jiy545.

PMID:
30239832
35.

Seropositivity to Multiple Anogenital Human Papillomavirus (HPV) Types Is Associated With Current Anogenital HPV Infection, Abnormal Cytology, and Seropositivity for Nongenital HPVs.

Faust H, Artemchuk H, Oštrbenk A, Triglav T, Poljak M, Dillner J.

J Infect Dis. 2019 Jan 9;219(3):489-496. doi: 10.1093/infdis/jiy523.

PMID:
30202984
36.

HPV-mRNA and HPV-DNA detection in samples taken up to seven years before severe dysplasia of cervix uteri.

Forslund O, Miriam Elfström K, Lamin H, Dillner J.

Int J Cancer. 2019 Mar 1;144(5):1073-1081. doi: 10.1002/ijc.31819. Epub 2018 Oct 4.

PMID:
30125346
37.

Author's reply to: Implementation and organization of cancer screening in France.

Basu P, Ponti A, Anttila A, Ronco G, Senore C, Vale DB, Segnan N, Tomatis M, Soerjomataram I, Žakelj MP, Dillner J, Elfström KM, Lönnberg S, Sankaranarayanan R.

Int J Cancer. 2018 Dec 1;143(11):3035. doi: 10.1002/ijc.31629. Epub 2018 Oct 3. No abstract available.

38.

ICTV Virus Taxonomy Profile: Papillomaviridae.

Van Doorslaer K, Chen Z, Bernard HU, Chan PKS, DeSalle R, Dillner J, Forslund O, Haga T, McBride AA, Villa LL, Burk RD, Ictv Report Consortium.

J Gen Virol. 2018 Aug;99(8):989-990. doi: 10.1099/jgv.0.001105. Epub 2018 Jun 21.

39.

[Cervical cancer has increased in Sweden in women who had a normal cell sample].

Dillner J, Sparén P, Andrae B, Strander B.

Lakartidningen. 2018 Jun 5;115. pii: E9FD. Swedish.

40.

Human Papillomavirus Serology Among Women Living With HIV: Type-Specific Seroprevalence, Seroconversion, and Risk of Cervical Reinfection.

Kelly H, Faust H, Chikandiwa A, Ngou J, Weiss HA, Segondy M, Dillner J, Delany-Moretlwe S, Mayaud P.

J Infect Dis. 2018 Aug 14;218(6):927-936. doi: 10.1093/infdis/jiy252.

41.

Gender-neutral vaccination provides improved control of human papillomavirus types 18/31/33/35 through herd immunity: Results of a community randomized trial (III).

Lehtinen M, Luostarinen T, Vänskä S, Söderlund-Strand A, Eriksson T, Natunen K, Apter D, Baussano I, Harjula K, Hokkanen M, Kuortti M, Palmroth J, Petäjä T, Pukkala E, Rekonen S, Siitari-Mattila M, Surcel HM, Tuomivaara L, Paavonen J, Nieminen P, Dillner J, Dubin G, Garnett G.

Int J Cancer. 2018 Nov 1;143(9):2299-2310. doi: 10.1002/ijc.31618. Epub 2018 Aug 10.

42.

Determinants of the presence of human papillomaviruses in the anal canal of Russian men.

Smelov V, Elfström KM, Eklund C, Sokolova O, Dillner J.

J Med Virol. 2018 Oct;90(10):1643-1650. doi: 10.1002/jmv.25234. Epub 2018 Jun 12.

PMID:
29797586
43.

Decline of HPV infections in Scandinavian cervical screening populations after introduction of HPV vaccination programs.

Dillner J, Nygård M, Munk C, Hortlund M, Hansen BT, Lagheden C, Liaw KL, Kjaer SK.

Vaccine. 2018 Jun 18;36(26):3820-3829. doi: 10.1016/j.vaccine.2018.05.019. Epub 2018 May 31.

PMID:
29778519
44.

Viremia preceding multiple sclerosis: Two nested case-control studies.

Hultin E, Mühr LSA, Bzhalava Z, Hortlund M, Lagheden C, Sundström P, Dillner J.

Virology. 2018 Jul;520:21-29. doi: 10.1016/j.virol.2018.04.006. Epub 2018 May 14.

45.

Suppressive antiretroviral therapy associates with effective treatment of high-grade cervical intraepithelial neoplasia.

Carlander C, Wagner P, van Beirs A, Yilmaz A, Elfgren K, Dillner J, Sönnerborg A, Sparén P.

AIDS. 2018 Jul 17;32(11):1475-1484. doi: 10.1097/QAD.0000000000001853.

PMID:
29746299
46.

Estimating effectiveness of HPV vaccination against HPV infection from post-vaccination data in the absence of baseline data.

Vänskä S, Söderlund-Strand A, Uhnoo I, Lehtinen M, Dillner J.

Vaccine. 2018 May 31;36(23):3239-3246. doi: 10.1016/j.vaccine.2018.04.073. Epub 2018 Apr 30.

PMID:
29716776
47.

Towards quality and order in human papillomavirus research.

Mühr LSA, Eklund C, Dillner J.

Virology. 2018 Jun;519:74-76. doi: 10.1016/j.virol.2018.04.003. Epub 2018 Apr 18.

48.

Invitation strategies and coverage in the population-based cancer screening programmes in the European Union.

Vale DB, Anttila A, Ponti A, Senore C, Sankaranaryanan R, Ronco G, Segnan N, Tomatis M, Žakelj MP, Elfström KM, Lönnberg S, Dillner J, Basu P.

Eur J Cancer Prev. 2019 Mar;28(2):131-140. doi: 10.1097/CEJ.0000000000000426.

PMID:
29570103
49.

Nationwide comprehensive human papillomavirus (HPV) genotyping of invasive cervical cancer.

Lagheden C, Eklund C, Lamin H, Kleppe SN, Lei J, Elfström KM, Sundström K, Andrae B, Sparén P, Dillner J.

Br J Cancer. 2018 May;118(10):1377-1381. doi: 10.1038/s41416-018-0053-6. Epub 2018 Mar 21.

50.

Seroprevalences of Antibodies to 11 Human Papillomavirus (HPV) Types Mark Cumulative HPV Exposure.

Artemchuk H, Triglav T, Oštrbenk A, Poljak M, Dillner J, Faust H.

J Infect Dis. 2018 Jul 2;218(3):398-405. doi: 10.1093/infdis/jiy107.

PMID:
29529245

Supplemental Content

Loading ...
Support Center